Share on StockTwits
 

La Jolla Pharmaceutical Company (NASDAQ:LJPC) CEO George F. Tidmarsh purchased 3,000 shares of the company’s stock on the open market in a transaction that occurred on Friday, February 7th. The shares were purchased at an average cost of $7.25 per share, for a total transaction of $21,750.00. Following the completion of the transaction, the chief executive officer now directly owns 1,391,086 shares of the company’s stock, valued at approximately $10,085,374. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of La Jolla Pharmaceutical Company (NASDAQ:LJPC) traded up 4.10% on Tuesday, hitting $7.61. 19,333 shares of the company’s stock traded hands. La Jolla Pharmaceutical Company has a one year low of $3.00 and a one year high of $12.00. The stock has a 50-day moving average of $8.06 and a 200-day moving average of $6.72. The company’s market cap is $33.5 million.

Separately, analysts at Noble Financial initiated coverage on shares of La Jolla Pharmaceutical Company in a research note on Monday, December 16th. They set a “buy” rating on the stock.

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the development of treatments that inhibits the activity of galectins as a means of treating human diseases, such as cancer and chronic organ failure.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.